Dr. Reddy's Laboratories has reported results for fourth quarter and year ended March 31, 2017.
The company has reported net profit of Rs 223 crore for the quarter ended March 31, 2017 as compared to net loss of Rs 38.60 crore for the same quarter in the previous year. However, total income of the company decreased by 3.43% at Rs 2419.60 crore for quarter under review as compared to Rs 2505.50 crore for the quarter ended March 31, 2016.
On consolidated basis, the company has reported around three fold rise in its net profit after tax and share of profits of associates at Rs 337.60 crore for the quarter ended March 31, 2017 as compared to Rs 122.60 crore for the same quarter in the previous year. However, total income of the company decreased by 6.38% at Rs 3632.40 crore for quarter under review as compared to Rs 3880 crore for the same quarter ended previous year.
For the year ended March 31, 2017, the company has posted a marginal rise of 0.71% in its net profit at Rs 1384.10 crore as compared to Rs 1374.30 crore in FY16. However, total income of company decreased by 2.88% at Rs 10311 crore for year under review as compared to Rs 10616.80 crore for the year ended March 31, 2016.
For the year ended March 31, 2017, on the consolidated basis, the company has posted a fall of 39.36% in its net profit after tax and share of profits of associates at Rs 1292.10 crore as compared to Rs 2130.60 crore in the previous year. Total income from operations of the company decreased by 9.43% at Rs 14367.60 crore for year under review as compared to Rs 15863.30 crore for the year ended March 31, 2016.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: